Shandong SaiTuo Bio-Tech's controlled subsidiary Shandong Sirui Pharmaceutical recently received the Chemical API Marketing Application Approval Notification for fluticasone furoate from the National Medical Products Administration. Fluticasone furoate is a potent glucocorticoid used in nasal sprays to treat seasonal and perennial allergic rhinitis in patients aged two years and older, and in dry powder inhalers for asthma and chronic obstructive pulmonary disease. The company stated that this approval will further enrich its product pipeline and enhance its market competitiveness in the chemical API sector. However, there are currently no sales of this API, and the timing of production and sales is uncertain due to factors such as the progress of GMP compliance inspections and changes in the market environment. According to IQVIA data, global demand for fluticasone furoate API in 2024 was approximately 500 kilograms.
Shandong Sito Bio-technology Co LtdSubsidiary receives marketing approval for fluticasone furoate API, enriching product pipeline and enhancing competitiveness.
Directly receives the marketing approval notification for fluticasone furoate API from NMPA.